Fate can be altered

Discovering and developing first-in-class small molecule drugs for improved treatment of diseases with significant clinical need.

More info More info


We aim to become globally recognized for developing breakthrough therapies to treat incurable diseases. Through intelligent identification and validation of protein and mRNA targets that drive disease progression and modulating their activity with small molecules, we strive to change the fate of patients by stopping the progression and reversing the effects of diseases with unmet medical need.

More info More info


Molecure’s exceptional in-house medicinal chemistry, biology and discovery capabilities allied to novel target biology gained from leading universities worldwide has enabled us to create a broad pipeline of drug candidates targeting unique and unexplored protein targets, as well as a cutting-edge small molecule mRNA targeting discovery platform.

Discover our pipeline Discover our pipeline


On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights

31 October 2023

Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum

29 September 2023

Invitation to investor meeting 3rd October 2023, 2:00 pm (CET)

20 September 2023

Join us

People are the foundation of Molecure’s success. Our scientists are the creators of the best ideas for the multiple new small molecule medicines that are invented in the laboratories. The Molecure team works together to discover the therapies needed to improve the treatment of previously incurable diseases.
It is this unified goal that guides us every day. We are inspired by science, we discover and create. For us, work is a passion.

More info More info
This site is registered on wpml.org as a development site.